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Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81 A71OA-pain intensity is strongly associated with loss of function and quality
of life. To date, it is unclear if NP alone, as a reﬂection of CS is associated
with los of (joint speciﬁc) function and quality of life in patients with hip
or knee OA. The primary aimof this study is therefore; to investigate if NP
is associated with loss of joint speciﬁc patient-centered functional out-
comes and Health Related Quality of life (HRQOL). The secondary aim is
to investigate the relationship between NP and centrally mediated
symptoms (mood, fatigue, sleep quality) and symptoms associated with
CS (widespread pain, illness burden, pain intensity at rest).
Methods: 299 adult primary OA-patients (139 hip-OA, 160 knee-OA)
completed a questionnaire survey bymail. The survey involved questions
about demographic characteristics, OA-pain duration, previous joint
surgery, widespread pain and comorbidities. Subsequently, themodiﬁed-
painDETECT questionnaire (mPDQ; to measure NP), the Knee or Hip
injury and Osteoarthritis Outcome Score (KOOS/HOOS; to measure joint
speciﬁc patient-centered functional outcomes), the Short Form-36 (SF-
36; to measure HRQOL), a joint pain Numeric Rating Scale, a Visual Ana-
logue Scale for joint pain at rest and the Pittsburgh Sleep Quality Index
were administered. Patients were grouped based on their mPDQ-score,
the ﬁrst group (n¼184) involved patients with a nociceptive pain phe-
notype (mPDQ score 12), the second group (n¼115) represented a
possible or likely neuropathic pain phenotype (mPDQ score >12).
Differences between groups were analyzed in case of continues varia-
bles by means of an independent samples t-test (non-parametric
equivalent in case of skewness). For non-continues data a Chi-square or
a Fisher’s exact test was used. A p-value of <0.05 is considered stat-
istically signiﬁcant.
Results: Ninety-two percent of the mPDQ-scores were non-zero and
38.5% of the total population corresponding to a possible or likely NP-
phenotype (hip-OA: 34.5%; knee-OA: 41.9%). The NP-group scored sig-
niﬁcantly higher on bodymass index (BMI), pain intensity, duration and
pain medication usage. None of the patients used non conventional
centrally acting pain medication. No signiﬁcant differences were
observed based on the presence of previous joint surgery. After
adjusting for relevant covariates like; sex, age, BMI, pain intensity and
pain duration: possible or likely NP was signiﬁcantly associated with
loss of joint speciﬁc outcomes on all 5 subscales of the KOOS/HOOS
(mean difference 9.8 points). This goes along with signiﬁcant loss of
HRQOL on the SF-36 dimensions “Physical Functioning” and “Bodily
Pain”. Furthermore, the NP phenotype was to a large extend sig-
niﬁcantly associated (adjusted for sex, age, BMI) with centrally medi-
ated symptoms (mood, p<0.05; fatigue, p<0.05; sleep quality, p¼0.062)
and features associated with CS (widespread pain, p<0.001; illness
burden, p<0.075; pain at rest, p<0.001).
Conclusions: The results indicate that NP -independent from pain
intensity and pain duration- is mainly associated with clinical relevant
loss of the physical (hip/knee speciﬁc) and functional aspects of HRQOL.
Due to the high prevalence of NP in OA-patients and the found asso-
ciation with centrally mediated symptoms and possible CS; it seems to
be justiﬁed to treat NP-patients more speciﬁcally with non-conven-
tional centrally acting pain medication.
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GENETIC VARIANTS IN THE SUPT3H-RUNX2 LOCUS CONFER
SUSCEPTIBILITY FOR BONE AND CARTILAGE RELATED DISORDERS
VIA LONG-RANGE REGULATION OF RUNX2
C.G. Boer y, R. Narcisi y, Y.F. Ramos z, W. den Hollander z, N. Bomer z,
M. C. Castano Betancourt y, A.G. Uitterlinden y, G. van Osch y,
I. Meulenbelt z, J.J. van Meurs y. y Erasmus Med. Ctr., Rotterdam,
Netherlands; z Leiden Univ. Med. Ctr., Leiden, Netherlands
Purpose: Genome-wide association studies (GWAS) have identiﬁed in
total 6 independent SNPs within the 5’ region of the RUNX2 gene to be
associated to cartilage and bone related phenotypes. We hypothesize
that these SNPs may regulate RUNX2 expression in a time- and differ-
entiation depended manner. In this way, these SNPs might regulate
cartilage and bone differentiation, which result in the multitude of
associations found in this region. Therefore we aim to elucidate the
effect of the identiﬁed SNPs on the regulation and expression of RUNX2
and how these confer susceptibility to cartilage and bone related dis-
orders, such as osteoarthritis and bone mineral density.
Methods: Independent GWAS signals were identiﬁed with linkage dis-
equilibrium (LD) data from the HapMap project and GCTA conditional
joint analysis. SNPs in LD with the GWAS loci were identiﬁed with the
SNAP tool and HaploReg (V2.2, Broad Institute). GWAS SNPs and SNPs inhigh LD were analyzed for enrichment in genomic regulatory regions,
and co-locationwithDNAbinding proteins using data from the ENCODE-
Project, Roadmap epigenetics project, Vista enhancer browser and the
FANTOM5database. In 96 chondrocytes fromexpanded human cartilage
samples for which GWAS-data was available, RUNX2-expression was
measured by RNA-sequencing, afterwhich eQTL analysis was performed
to determine the effect of the SNPs on gene expression. CTCF protein
binding was determined by ChIP-qPCR in human cartilage explants.
Results:Wehave identiﬁed7 SNPs in the5’regionof RUNX2 tobe robustly
associated to height (2 independent loci), bone mineral density (BMD),
osteoarthritis (OA, 2 independent loci),minimal joint spacewidth (mJSW)
and ossiﬁcation of the spine (OPPL) (see ﬁgure 1). Using LD data from the
GWAS signals we observed that 6 GWAS signals were independent of
another, but one of the signals formJSWwas inhigh LDwith that of hipOA
mJSW (r2 >0.8). Next we analysed all GWAS signals for enrichment in
genomic regulatory regions. All independent GWAS signals co-localized
to regions with enrichment of active enhancer markers, H3K4me1,
H3K27ac and DNase1 hypersensitivity enrichment and bi-directional
CAGE reads, in osteoblast and chondrogenic cells.
CTCF (CCCTC-binding factor or 11-zinc ﬁnger protein) is essential for
chromatin organization and gene regulation, its functions include tran-
scription initiationand the formationof long-rangechromatin interactions.
TheBMDassociated SNPswere situated in an area that is involved inCTCF-
binding in osteoablasts. These SNPs are located ~700 kb away from the
RUNX2 promoter, yet they do have a signiﬁcant effect (p<0.05) on RUNX2
gene expression in human cartilage (as quantiﬁed by RNAseq in 96 sam-
ples). In addition,weobservedthatwhenwestimulatedRUNX2expression
in human chondrocytes by TGFb stimulation, there is also an increase in
CTCF binding near the RUNX2 promoter. These results suggest that CTCF
binding may play a role in the regulation of RUNX2 gene expression.
Conclusions:We have shown that variants in the SUPT3H-RUNX2 locus
associated to cartilage and bone phenotypes are located in potential gene
regulatory regions, and effect RUNX2 gene expression. We hypothesize
that the SNPs are localized in long-range enhancers which, mediated by a
CTCF chromatin-loop to the RUNX2 promoters, regulate RUNX2 gene
expression in a time-and differentiation dependent manner during car-
tilage and bone development. Future studies will further investigate the
chromatin architecture of the SUPT3H-RUNX2 locus.
Figure 1. SNPs found in GWAS located in the SUPT3H-RUNX2 locus are
associated to bone and cartilage phenotypes.
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METHYLATION OF CARTILAGE DNA IS A MEDIATOR OF GENETIC RISK
AT SEVERAL OA SUSCEPTIBILITY LOCI
M.D. Rushton, L.N. Reynard, D.A. Young, C. Shepherd, R. Darlay,
H.J. Cordell, J. Loughlin. Newcastle Univ., Newcastle upon Tyne, United
Kingdom
Purpose: Replicated OA genetic risk loci are now emerging through the
use of powerful case-control association studies. The analysis of the
epigenetics of OA has also received considerable attention in the last few
years, particularly CpG methylation in cartilage chondrocyte genomic
DNA. The vast majority of OA risk loci reported to date do not contain
amino-acid substitution polymorphisms that can account for the asso-
ciation signal, implying that OA risk alleles act by modulating gene
expression rather than by changing protein sequence. DNAmethylation
is a mechanism used by the cell to regulate gene expression and DNA
methylation is known to mediate genetic risk in several diseases
including rheumatoid arthritis. In this study we assessed whether DNA
methylation is an intermediary of OA genetic risk by correlating geno-
type at OA risk loci with cartilage DNA CpG methylation.
Methods: In the discovery analysis, DNAwas collected from the cartilage
of 110 elderly individuals. Seventy one of thesewere OA knee patients, 20
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OA. Genome-wide DNA methylation proﬁling was carried out on the
bisulphite converted DNA of these 110 patients using the Inﬁnium
HumanMethylation450 BeadChip (Illumina). For each CpG, the data was
represented as a b value ranging from 0 (no methylation) to 1 (100%
methylation). A replication cohort of 47 elderly individuals (29 OA knee,
13OAhip and 5NOF samples)was taken forward formethylation analysis
by pyrosequencing. Genotyping was performed on the cartilage DNA
using the HumanOmniExpress Bead Chip (Illumina) for the 110 patients
and RFLP assays for the 47 patients. Gene expression comparisons were
performed using previously published data and directly by real-time
quantitative PCR on cartilage cDNA. Sixteen OA risk loci were studied,
including well-deﬁned candidates such as GDF5 and DIO2, and signals
fromgenome-wide association scans such as those from the arcOGENand
Rotterdam studies. Genotype at the SNP that had originally identiﬁed the
association signal was correlated with CpG methylation levels by logistic
regression. For each locus we covered the whole association interval (as
deﬁnedby linkagedisequilibrium) and studied all of the CpGs fromwithin
that region that are part of the HumanMethylation450 BeadChip array.
The number of CpGs therefore ranged from 57 (the chromosome 9q
arcOGEN locus) to 655 (the MCF2L locus). P-values were corrected for
multiple testing using the Benjamini-Hochberg method and were
adjusted for the number of CpGs studied. For the discovery phase we
studied the methylation data for all 110 individuals and following strat-
iﬁcation to OA-only (91 individuals). If relevant, we also investigated the
particular strata of OA that had originally been used to detect the asso-
ciation signal. For example, the arcOGEN RUNX2/SUPT3H locus (dis-
covered using SNP rs10948172) is only relevant to disease occurrence in
males and we therefore studied males-only as part of our analysis of this
locus. The same stratiﬁed approach was applied to the replication cohort.
Results: In the discovery analysis of the 110 patients ﬁve of the 16 risk
loci harbored CpGs whose methylation correlated with genotype at the
association SNP. These were the GNL3/GLT8D1, RUNX2/SUPT3H, MCF2L,
ALDH1A2 and GDF5 loci. Themost signiﬁcant p-valuewas 9.42x10-9 for
CpG probe cg18099408 within the GNL3/GLT8D1 locus. All 5 signals
replicated and in the same direction as in the discovery analysis
(p<0.05), with the p-value for cg18099408 in the replication cohort
being 0.009. The RUNX2/SUPT3H locus demonstrated a correlation
between genotype and methylation status only in the male strata,
perfectly matching the genetic result for this locus. For this locus,
methylation of four CpGs that cluster together correlated with genotype
at rs10948172, with the most signiﬁcant p-value being 4.4x10-7 for CpG
probe cg18551225. All four CpGs replicated in males (p<0.05). Gene
expression correlated with methylation at 3 of the 5 replicating signals
but not with MCF2L or RUNX2/SUPT3H, implying that the functional
effects at these two loci may have been active during earlier stages of
cartilage development.
Conclusions: Our study reveals that a high proportion of OA suscepti-
bility loci correlate with and therefore potentially regulate the level of
DNA methylation in cis, so called methylation quantitative trait loci or
meQTLs. It therefore provides us with a mechanistic explanation as to
how these loci impact upon OA susceptibility, with DNA methylation
acting as an intermediary of OA genetic risk.
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THE CARBOHYDRATE SULFOTRANSFERASE GENE CHST11 IS
REGULATED BY DNA METHYLATION WHICH IMPACTS ON THE
FUNCTIONAL EFFECT OF THE OA GENETIC SUSCEPTIBILITY
RESIDING AT THIS LOCUS
L.N. Reynard, J. Loughlin. Newcastle Univ., Newcastle upon Tyne, United
Kingdom
Purpose: The carbohydrate sulfotransferase gene CHST11 encodes an
enzyme that plays an important role in chondrogenesis by regulating the
sulphation of glycosaminoglycans in the cartilage extracellular matrix.
SNP rs835487, located within the gene, is associated with hip OA at the
genome-wide signiﬁcance level in European populations (p¼1.64x10-8).
Several CpG sites within CHST11 are aberrantly methylated in human OA
cartilage and this gene is up-regulated in both OA hip and OA knee car-
tilage. We have previously reported allelic differences in enhancer
activity of rs835487 and of rs835488, which is in perfect linkage dis-
equilibriumwith rs835487, forming a single haplotype. This allelic effect
is mediated by differences in binding of the transcription regulator
proteins SP1, SP3, YY1 and SUB1 to the two alleles of the haplotype.
rs835487 and rs835488 reside within intron 2 of CHST11 in an enhancerregion that we hypothesis acts as a regulator of CHST11 expression. There
are several CpG sites within this enhancer region, including one created
by the C allele of rs835488, suggesting DNA methylation could modulate
the OA genetic effect on CHST11 enhancer activity. The aims of this study
were to: A) determine if DNA methylation regulates CHST11 expression;
B) examine if there is altered methylation of the rs835487-rs835488
enhancer region in OA cartilage, and if so; C) understand what affect this
has on protein binding to and regulatory activity of the enhancer.
Methods: Isolated human primary chondrocytes (HACs) and trans-
formed human cell lines were cultured with the demethylating agent 5-
aza-2ʹdeoxycytidine (AZA) for 3 population doublings and CHST11
expression measured by qRT-PCR. Methylation of 3 CpG sites within the
enhancer was assayed by pyrosequencing after bisulphite conversion of
genomic DNA that was extracted frommacroscopically normal cartilage
obtained fromOA hip, OA knee or neck-of-femur (NOF) fracture patients
after joint replacement surgery. The CpG sites were located 10bp
downstream of rs835487, rs835488 itself and 34bp downstream of
rs835488. The affect of DNA methylation on protein binding to and
enhancer activity of the rs835487 and rs835488 SNPs was investigated
using electrophoretic mobility shift assays (EMSAs) and in-vitro
methylation luciferase assays respectively.
Results: CHST11 was upregulated in HACs (2-fold, p¼0.008) and human
cell lines after AZA treatment. All 3 enhancer CpG sites assayed were
signiﬁcantly hypermethylated inOAhip andOAknee cartilage relative to
the NOF control cartilage (p<0.0001). Methylation level of the rs835488
CpG site was affected by rs835488 genotype in OA cartilage (OA hip
CT¼17.3%, CC¼33.2%; OA knee CT¼16.4%, CC¼29.6%), but, surprisingly,
not in NOF cartilage, where individuals homozygous and heterozygous
for the CpG site had similar levels of methylation (CT¼10%, n¼14;
CC¼12.1%, n¼15). Methylation of the 3 enhancer CpG sites also corre-
lated with additional CHST11 CpG sites outside of this region (up to
100kb away), including the cg00608861 and cg11117177 CpG sites pre-
viously identiﬁed as differentially methylated in OA cartilage. Again,
these correlations were speciﬁc to OA cartilage, with the strongest cor-
relations observed in OA hip cartilage. In EMSAs, methylation of the
rs835487 þ10CpG site increased binding of an unknown protein spe-
ciﬁcally to theAallele of rs835487but hadnoaffect on thebindingof SP1,
SP3 or SUB1 to either allele. SP1, SP3, YY1 and SUB1 boundmore avidly to
the methylated C allele than unmethylated C allele of rs835488, with an
unidentiﬁed protein-complex binding only to the methylated allele.
Methylation therefore represses enhancer activity of the rs835487-
rs835488 region in a haplotype-dependent manner.
Conclusions: Our results demonstrate that methylation of the
rs835487-rs835488 enhancer region has a signiﬁcant effect on tran-
scription factor binding to these OA susceptibility SNPs, with methyl-
ation altering the regulatory activity of this region. There is therefore a
clear functional link between genetic risk and methylation status at the
CHST11 OA susceptibility locus. Since DNA methylation is inﬂuenced by
lifestyle, age and disease status our data implies that the functional
effect of the rs835487 and rs835488 risk haplotype may change under
different environmental situations, affecting its penetrance on OA risk.
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DIFFERENTIAL DNA METHYLATION AND REDUCED EXPRESSION OF
CRITICAL TRANSCRIPTION FACTORS IN HUMAN OA CARTILAGE
O. Alvarez-Garcia, K.M. Fisch, R. Akagi, A.I. Su, M.K. Lotz. The Scripps Res.
Inst., La Jolla, CA
Purpose: DNA methylation is the most characterized epigenetic
mechanism and has been recently linked to knee osteoarthritis (OA)
pathogenesis. While genome wide methylation studies have shown
substantial differences between normal and OA articular cartilage,
those studies have important limitations: a) most studies compared OA
articular cartilage from different joints without including a proper
control group, b) the functional consequences of differentially methy-
lated genomes were normally assessed by transcriptional analysis of a
small group of genes of interest, and c) the resulting link between DNA
methylation and transcription was not further validated in an exper-
imental setting. All these limitations prompted us to design a study
aimed to comprehensively integrate the methylome and transcriptome
of normal and OA knee articular cartilage using the Illumina Inﬁnium
HumanMethylation450 beadchip array and next generation RNA
sequencing, respectively. Furthermore, we used different in vitro
approaches to experimentally validate the link between DNA methyl-
ation and gene expression in human chondrocytes.
